CorMedix Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph Todisco
- Full Time Employees
- 191
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Connell Drive Berkeley Heights NJ United States of America 07922
- IPO Date
- May 13, 2010
- CIK
- 0001410098
- Website
- cormedix.com
- Similar Companies
- Business
- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening infectious and inflammatory diseases, primarily targets hospital and dialysis settings in the United States with expanding international presence. Founded in 2006 and headquartered in Berkeley Heights, New Jersey, the company offers DefenCath (taurolidine and heparin catheter lock solution), the first and only FDA-approved antimicrobial therapy to reduce catheter-related bloodstream infections in adult hemodialysis patients via central venous catheters; following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix also commercializes an expanded portfolio of anti-infective products including MINOCIN (minocycline for infections), REZZAYO (rezafungin for candidemia and invasive candidiasis), VABOMERE (meropenem and vaborbactam for urinary tract and complicated intra-abdominal infections), ORBACTIV (oritavancin for acute bacterial skin and skin structure infections), BAXDELA (delafloxacin for skin infections and community-acquired bacterial pneumonia), KIMYRSA (oritavancin for bloodstream and skin infections), and TOPROL-XL (metoprolol succinate for cardiovascular conditions). The company conducts ongoing clinical studies for DefenCath in total parenteral nutrition, pediatric, and oncology patient populations, while REZZAYO advances in a Phase III trial for prophylaxis of invasive fungal infections in allogeneic blood and marrow transplant patients, with topline results expected in Q2 2026. Recent developments include the transformative September 2025 completion of the Melinta Therapeutics acquisition, which diversifies the product portfolio, raises pro forma 2025 revenue guidance to $325-350 million, projects annual synergies of $35-45 million, and introduces enhanced leadership in hospital acute care; in October 2025, DefenCath earned Innovative Technology Designation from Vizient for its clinical impact on infection prevention; third-quarter 2025 results reported $104.3 million in net revenue and $130.8 million pro forma, driven by commercial launches and market penetration.
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Q1 Earnings Call Highlights
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
CorMedix: A Shrinking Core And No Proven Second Engine
CorMedix to Participate in Needham Virtual Healthcare Conference
Phocas Financial Corp. Takes $1.99 Million Position in CorMedix Inc $CRMD